A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,212
Proportion of subjects achieving clinical response at Week 16 relative to the Baseline (Week 0) PASI score
Time frame: Week 16
Safety parameters
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.